Corrigendum

View correction statement:

Erratum

Corrigendum

Corrigendum

This article refers to:

Real-World Use and Acceptance of Rituximab Biosimilars in Non-Hodgkin Lymphoma in an Oncologist Network in Germany

The Short Communication by Burkhard Otremba, Jens Borchardt, Andra Kuske, Maike Hollngel-Schmitz & Florian O Losch, ‘Real-world use and acceptance of rituximab biosimilars in non-hodgkin lymphoma in an oncologist network in Germany’, which appeared in the May 2020 issue of Future Oncology 16(15), 1001–1012, was published with an error in Figure 1. The corrected figure is included below.

Figure 1. Distribution of patients included in the database according to the International Classification of Diseases code indication.

DLBCL: Diffuse large B-cell lymphoma; ICD: World Health Organisation International Classification of Diseases; NHL: Non-Hodgkin Lymphoma; NK: Natural killer; MCL: Mantle cell Lymphoma; MZL: Marginal zone lymphoma.

The authors and editors of Future Oncology would like to sincerely apologize for any inconvenience or confusion this may have caused our readers.